Valneva begins Phase I/II study of Covid-19 vaccine candidate,

France-based specialty vaccine company Valneva has commenced the Phase I/II VLA2001-201 clinical study of its Covid-19 vaccine candidate, …, France-based specialty vaccine company Valneva has commenced the Phase I/II VLA2001-201 clinical study of its Covid-19 vaccine candidate, …, Read More

Scroll to Top